Literature DB >> 6160015

Aging and renal clearance of procainamide and acetylprocainamide.

M M Reidenberg, M Camacho, J Kluger, D E Drayer.   

Abstract

Thirty-two patients had blood and urine collected simultaneously for measurement of procainamide, acetylprocainamide, and creatinine. The ratios of drug clearance to creatinine clearance were calculated for each. The procainamide:creatinine clearance ratio averaged 2.9 +/- 1.6 (SD) and fell as age of the patients rose (r = 0.5, p < 0.01). The acetylprocainamide:creatinine clearance ratio averaged 1.7 +/- 0.8 and also fell with age. The combination of decline in overall renal function with age with this decrease in the rate of renal tubular secretion of these drugs led to a progressive age-related rise in the steady-state serum level of procainamide (r = 0.56, p < 0.01) and acetylprocainamide (r = 0.36, p < 0.1) achieved by any dose of procainamide. Thus, the dosage of procainamide must be individualized for both overall renal function (GFR) and the age-related variations in renal tubular secretion that are of most note in children and the elderly.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160015     DOI: 10.1038/clpt.1980.228

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

2.  Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects.

Authors:  R A Blouin; J Kneer; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Amiloride disposition in geriatric patients: importance of renal function.

Authors:  A Somogyi; D Hewson; M Muirhead; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

4.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.

Authors:  A Somogyi; A McLean; B Heinzow
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Pharmacokinetics of enprofylline in healthy elderly subjects.

Authors:  E Lunell; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Influence of advanced age on the disposition of acetazolamide.

Authors:  D J Chapron; K R Sweeney; P U Feig; P A Kramer
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

9.  Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites.

Authors:  M F Fromm; S Botsch; G Heinkele; J Evers; H K Kroemer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.

Authors:  J H Lin; A N Chremos; K C Yeh; J Antonello; G A Hessey
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.